Quince Therapeutics Inc., a biotechnology company focused on treating rare diseases, has announced the successful closing of a private placement of securities, raising approximately $11.5 million in upfront proceeds. The financing, which was priced at a premium, was led by Nantahala Capital, a healthcare-focused institutional investor, with participation from existing Quince shareholders such as ADAR1 Capital Management and members of Quince's senior management. The private placement includes common stock and accompanying warrants, with potential additional proceeds of up to $10.4 million if the warrants are exercised in full for cash. The funds will be used for working capital, general corporate purposes, and to advance the company's pivotal Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T), as well as to explore new program expansions into Duchenne muscular dystrophy and other rare diseases. This financing extends Quince's cash runway into at least the second quarter of 2026, supporting its ongoing research and development efforts.